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Why has Alzheimer’s disease (AD) remained a conundrum today? The main reason is
the stagnation in understanding the origins of plaques and tangles. While they are widely
thought to be the products of the “aberrant” pathways, we believe that plaques and
tangles result from natural aging. From this new perspective, we have proposed that
age-related inefficiency of α-secretase is the underpinning for Aβ overproduction. This
view contrasts sharply with the current doctrine that Aβ overproduction is the product of
the “overactivated” β- and γ-secretases. Following this doctrine, it has been claimed that
the two secretases are “positively identified” and that their inhibitors have “successfully
reduced Aβ levels.” But, why have these studies not led to the understanding of AD or
successful clinical trials? And if so, where did they go off course in reasoning? These
questions may touch the basics of biological science and must be answered. In this
paper, I dissected several prevailing assumptions and some influential reports with an
attempt to trace the origins of the conundrum. This work led me to an original model for
Aβ overproduction and also to a serious question: given the universal knowledge that
boosting α-secretase reduces Aβ, a straightforward highway for intervention, then why
is there such an obsession on “inhibiting β- and γ-secretases,” a much more costly and
twisting road even if possible? This issue requires the attention of policymakers and all
researchers. I therefore call for a game change in AD study.
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Introduction
Amyloid plaques and neurofibrillary tangles characterize aging human brains, and they are also
accompanying or correlating with the progression of late-onset sporadic Alzheimer’s disease (sAD;
also known as senile dementia or LOAD) in some elderly. As such, understanding their mechanism
of formation is essential for understanding sAD, but this mechanism has remained elusive after
intensive studies for decades (Masters and Beyreuther, 2006; O’Brien andWong, 2011; Nelson et al.,
2012).
Because plaques and tangles exist in essentially all elderly, we believe that they are the products
of aging or age-related insufficient proteolysis. From this new perspective, we have proposed that an
inefficient α-secretase in the normal processing of amyloid-β precursor protein (APP) is primarily
responsible for Aβ overproduction, and is also the rational drug target for intervention. This view
is in line with the knowledge that boosting APP α-processing reduces Aβ both in vitro and in vivo
(Chen, 1997; Chen and Fernandez, 2001).
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This knowledge, however, has been largely ignored by the field
where a dominant theory today is that Aβ overproduction is the
result of “overactivation” of “rate-limiting” β- and γ-secretases.
Following this doctrine, it has been reported that the two secre-
tases are “positively identified” and their inhibitors have “success-
fully reduced Aβ” (De Strooper et al., 2010; Selkoe, 2011). These
studies, however, have never convinced the medical community
as a whole, nor have been corroborated by the clinical trial results
(Chen and Nguyen, 2014). Thus, sAD has remained a major
scientific enigma of this century.
How has this happened? We have pointed out that redefin-
ing senile dementia (sAD) as a discrete/curable “disease” by the
National Institute on Aging (NIA) is the initial problem, which
mandates a “pathogenic” pathway, “independent of aging,” to be
found in a senile disorder that apparently results from population
aging (Chen et al., 2011a).
But, the current “β- and γ-secretases” doctrine has been pro-
moted by leading researchers, supported by mountain loads of
experimental results and published in top-notch journals. How,
then, can it be unconvincing to the general medical community
and, if so, where did it go off track in reasoning? In this paper,
I dissected several prevailing assumptions and some influential
reports with an attempt to trace the origins of the conundrum.
An Overly Stretched Picture of APP
Processing
It appears that many current problems are rooted in a commonly
used picture, which sketches the two pathways in APP processing
(Figure 1; among many similar ones). This picture, in concept,
rightly brings us to the core issues: the source of Aβ and the
process that produces it. It also vividly names the three proteases
involved as “secretase,” pointing to their unique roles in protein
secretion rather than degradation as most proteases do. Perhaps
owing to these merits, the picture has been used by almost all
investigators as a roadmap (ourselves included).
But, a truth is true only within its defined boundaries, and any
overstretching or over interpreting, even by a razor-thin deviation
off the boundaries, can sometimesmake it a fallacy with profound
consequences. Indeed, upon a re-examination with caution, it
came to my attention that the picture has been overstretched in
at least three key aspects.
(1) The two pathways, as the way they are drawn, can be taken to
imply that they occur at the same time, as such are independent
of each other. These implications, under the mandate of NIA
for a “pathogenic” pathway, have grown over the years from
trickle to flow and eventually to a full-blown doctrine. Which
posits that the amyloidogenic pathway is exactly the one that
NIA is looking for and thus only it, not α-pathway, is worth to
study (Selkoe, 2005; andmany studies on this pathway only) –
akin to a pathogen-induced pathway in patients only, not in
healthy individuals.
(2) If the two pathways occur at the same time, then they would
be expected to compete for APP. It thus seems plausible
to assume that the best way to explain Aβ overproduction
is by an “overactivation” or “overexpression” of β- and γ-
secretases, which liberate Aβ out of APP before α-secretase
Aβ APP
Normal Amyloidogenic
AβA β
Plaques
Aβ
γ-secretaseβ-secretaseα-secretase
FIGURE 1 | A commonly used picture for APP processing. It conveys a
general idea for two pathways and their end results. But the picture has been
overstretched in three key points: (i) the two pathways are thought to occur at
the same time, so they would be “independent” of each other and “compete”
for APP; (ii) as such, Aβ overproduction may be explained by an
“overactivated” amyloidogenic pathway; and (iii) the three secretases in
question are each depicted in a singular form, so they all seem to be
identifiable. These overstretches have led to many far-reaching consequences
in sAD study.
can act. This reasoning has cultivated the notion that β- and
γ-secretases are “rate-limiting” in the process, thus inhibiting
them would reduce Aβ “at its root” – age-related changes in
APP normal catabolism can be neglected.
(3) The three proteases in question are commonly depicted in
singular form, α-, β-, and γ-“secretase,” respectively. This
was miniscule, but today it is the cornerstone for enormous
efforts and resources devoted to the identification of β- and
γ-secretases and many clinical trials on their inhibitors. All it
is because the singular term carries with it a connotation that
there is only one protease releasing Aβ at its either end – its
singularity, a formidable premise.
Such overstretches of the picture, intentional or unintentional,
have pushed its boundaries to extreme and constituted the default
points for further ramifications in numerous studies. These stud-
ies reinforce, rationalize, and defend one other and together they
have generated numerous papers, patents and excitements. But
why has sAD remained an enigma? It may be because, at least in
part, they have not explained several hard questions.
(a) By what molecular mechanism can proteases be overactivated
or overexpressed during normal and early aging?
(b) Even if they are somehow overactivated or overexpressed by
an as-yet-unknown mechanism, but where do the additional
full-length APPs, the necessary precursors for overproducing
Aβs, come from?
(c) Even if additional APPs are somehow available and Aβ is
generated somehowby overactivated β-/γ-secretases, but how
can it stay and resist the indiscriminate attacks by many non-
specific proteases in the brain? (This is themost bizarre puzzle
in sAD that must be explained by any models).
(d) Why does this “protease-resistance” not happen tomost other
proteins? This also questions the “protein misfolding” model,
since no aberrant structures have ever been found in Aβ, tau
or other co-deposited proteins tomake them selectively prone
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FIGURE 2 | A new model for the mechanism of Aβ overproduction in
sporadic AD. It emphasizes three key points: (1) the “two pathways” do not
occur at the same time, but years apart, in young and aging (A,B). By this view,
there is only one, α-processing pathway that exists in two functional states; and
only after it becomes inefficient during aging, can the “amyloidogenic” pathway
be “overactivated”; (2) α-secretase is a Ca2+-dependent protease that
recognizes APP in a specific and exclusive manner, like a “ligand–receptor” pair
(A). So after it becomes inefficient, full-length APPs would not be attacked by
any other proteases at the same site, so they will accumulate transiently as the
additional precursors to overproduce Aβs; and (3) the intact APPs are then
truncated by many non-specific proteases, which are depicted as β’s and γ’s in
plural forms, thereby producing Aβs in varying lengths (B).
to misfolding (Chen and Nguyen, 2014). Such structures may
not be found in the future, since they imply that plaques and
tangles would be inherited or unmodifiable – in fact, they can
be easily modified by various common approaches such as
physical exercises (García-Mesa et al., 2011).
A New Picture for APP Processing
These questions may have touched the basics of biological prin-
ciples and casted doubts on the scientific bases of the “β-/γ-
secretases” doctrine, thereby calling for fundamentally different
and innovative ideas to explain Aβ overproduction. To this end,
we have undertaken a bottom-up analysis of the basic issues in
sAD and, as a result, proposed an original model from a new
perspective of “aging and energy-Ca2+ deficits” (Chen and Fer-
nandez, 1999; Chen and Nguyen, 2014). Now, I elaborate the
model by emphasizing three key points (Figure 2).
First and foremost, the “two pathways” in sAD do not occur at
the same time, but years apart in two distinctive life stages: young
and aging (Figures 2A,B). By this view, there would be no “two
pathways” anymore, rather there is only one normal pathway that
exists in two functional states: only after it is inefficient during
aging, can the “amyloidogenic” pathway become prominent – or
seemingly “overactivated” – as a result. Hence, the only reasonable
way to reduce Aβ plaques is by activating α-processing, just like
activating lipid degradation reduces cholesterol plaques.
Second, α-secretase is a Ca2+-dependent protease that
recognizes APP in a specific and exclusive manner, like a
ligand–receptor duo (Figure 2A; the reasons for this unusual
relationship were discussed previously; Chen and Nguyen, 2014).
During aging, α-secretase is inefficient as a result of energy and
Ca2+ signaling deficits. This would lead to a transient increase of
full-length APPs, which are not attacked by any other proteases
at the α-site but are alternatively truncated by many non-specific
proteases at other sites. So their fragments surrounding the
α-site will be spared and deposited as Aβs with varying lengths
(Figure 2B). Thus, Aβ is protease-resistant but most other
proteins are not (i.e., only the substrates of Ca2+-dependent
proteases will deposit during aging).
Third, as many proteases can be involved in the later stage
of Aβ genesis, I depict them in plural forms, i.e., “β’s” and “γ’s,”
which stand for “β-site APP cleaving enzymes” (BACEs, as com-
monly used) and “γ-site APP cleaving enzymes,” respectively. As
unregulated proteases, their products can increase only after the
substrates have increased (Figure 2B).
Has “β-Secretase” been “Positively
Identified”?
The new model thus suggests that “identification of β- or γ-
secretase” as a single enzyme entity is a problematic concept in
inception, since Aβs appear to be similar to many other protein
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fragments or peptides in our body that are randomly produced by
various proteases.
Nevertheless, three prominent studies have claimed that they
identified a protease that is responsible for the cleavage of APP at
theAβ1position (“β-site”) and it also displays other presumed fea-
tures of the putative enzyme, thus called it “β-secretase” (Hussain
et al., 1999;Vassar et al., 1999;Yan et al., 1999). But caveats remain.
(a) The claim apparently rests on the assumptions that there is
only one protease clipping the Aβ1-site and that all Aβs have
uniform N-termini at that site. In reality, the observed N-
termini of Aβs start from a range of at least 13 amino acids,
which may involve the actions of other proteases (Chen and
Nguyen, 2014; and references therein).
(b) Even if all Aβs start from the same site, there is still a hard task
ahead: to prove that no other proteases can also act at that site.
This task is especially necessary as themain goal of the studies
is to develop inhibitors of the enzyme to reduce Aβ in vivo.
Evidently, this goal would not be feasible if other proteases
can also act at that site.
Can these other proteases be excluded fromAβ1-site clipping?
Thiswould require testing all proteases in the body and exclud-
ing them one by one – a mission formidable or impossible.
As a matter of fact, other β-site-cleaving proteases have been
found (Evin et al., 1994; Sinha et al., 1999), disproving the
“singularity” of β-secretase in concept.
Thus, it is more correct to say that the studies have identified
one of the proteases that together produce one type of Aβs
(starting at Aβ1 position). This would question the use of its
inhibitors to reduce the overall levels of Aβs (see below).
(c) The three studies also claim that the identified β-secretase is
“membrane-bound.” Notably, such a protease would have an
out-reaching limit and that limit is 12/13 amino acids from
the cell surface, as two elegant studies have shown (Maruyama
et al., 1991; Sisodia, 1992). The Aβ1-site is 28 amino acids
from the cell surface. And also, how can a single membrane-
bound protease, with its mobility hindered, generate hetero-
geneousN-termini of Aβs? (Comparewithmembrane-bound
α-secretase; see below).
Why Presenilins are Unlikely to be
“γ-Secretase”
At the same time, it has also been claimed that “γ-secretase” is
identified as presenilins (PS1 and PS2) with the active center at
D257 or D385 in PS1 (Citron et al., 1997; Wolfe et al., 1999).
Besides the required justifications for its “singularity”, “overactiva-
tion” by aging, and the heterogeneous C-termini of Aβs (ending at
a range of at least 12 amino acids), this claim also faces additional
questions.
First, if PS1 is “γ-secretase,” then how can it be overactivated
by each of its near-200 gene mutations known today (Figure 3A)?
10
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Young                    PS mutants                      Aging 
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FIGURE 3 |Why presenilin 1 (PS1) is unlikely to be γ-secretase, but likely
a Ca2+ channel. (A) A simplified drawing that highlights many mutations on
PS1. If it is a protease, then some mutations that are hundreds of amino acids
away from the “activity center” (D257/D385) would be unlikely to affect the
protease activity. However, if PS1 is a Ca2+ channel, then mutations anywhere
on it would all disturb the super-rapid Ca2+ channeling process with similar
consequences. (B) As Ca2+ channels, both PS1 and PS2 mutations will mostly
reduce Ca2+ entry, not extrusion, since energy may not change in the young
mutant hosts. By contrast, an energy crisis in elderly will mostly slow down
Ca2+ extrusion, not entry, a spontaneous process driven by the ion gradient.
Thus, both cases will end up in the same net result: reduced Ca2+ signaling
potency in the brain (in sub-millisecond or microsecond). (C) However, if Ca2+
is measured in cultured cells (by second or longer time intervals), its changes
caused by either mutations or aging will manifest as higher steady-state “levels.”
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Presumably, most pathological mutations cause human diseases
by loss-of-function (Kelley, 1992), so such a “gain-of-function”
mechanism would be rare or minority cases. Thus, the probability
that near-200mutations all render the protease more active would
be remote.
Second, more importantly, the mutant amino acids are spread-
ing everywhere on PS1, and many of them are as far as hundreds
of residues away from the D257 or D385 site and others are in
the outside of the cell (Figure 3A). By what mechanism can they
increase the protease cleavage?
Now, why do I believe that most mutations cause diseases
by loss-of-function? Because (i) most mutation-caused human
diseases are loss-of-function in molecular nature (e.g., Sickle
cell anemia, cystic fibrosis, early onset familial hearing loss or
atherosclerosis; Cotran et al., 1999); and (ii) our body is essentially
an efficient system after a long process of evolution, so mutational
changes in it are more likely to decrease, rather than increase, its
functionality.
These points are especially evident in the “Ca2+ channels”
model for PSs (Chen, 1998a). High frequency Ca2+ waves are by
far themost sensitive and “digital” information-carrying regulator
in our body (Putney, 1998). As such, Ca2+ channels must be
highly exquisite especially for cognition, the most delicate func-
tion of humans. Thus, although the near-200 mutations spread
everywhere on the PS1 channel, it is no difficult to see that they
will all disturb the super-fast passage of Ca2+ through the channel,
a process that occurs intermittently at an astonishing frequency of
over a thousand times per second (sub-millisecond or microsec-
ond) in the brain (Llinás andMoreno, 1998). Needless to say, such
an extraordinarily intricate and precise process would be highly
sensitive to any subtle changes in the conformation, affinity, or
electrostatic charges of the channel brought by the mutant amino
acids, no matter where they are located (Figure 3A). This may
be why all pathogenic mutations cause similar loss of memory
function in their hosts.
The model also suggests that PS mutations most likely slow
Ca2+ entry, not extrusion, in each entry-extrusion cycle since
the latter is energy-driven but young mutant hosts may not
have energy deficiency (Figure 3B). In contrast, age-related Ca2+
deficit should occur mainly as slowed Ca2+ extrusion, thanks to
the energy crisis in the elderly, but not Ca2+ entry, a process
driven by the steep ion gradient. Thus, both cases would end up in
the same net result: reduced Ca2+ signaling efficacy in the brain
(Figure 3B), which will lead to permanent and early inactivation
of α-secretase and calpain, thereby resulting in severe plaques and
tangles in the young mutant hosts. However, if Ca2+ is measured
in cultured aging cells, the reduced Ca2+ signaling potency would
manifest as higher steady-state Ca2+ “levels” (Figure 3C) (Chen
et al., 2011b; Nguyen et al., 2013).
There are numerous Ca2+ channels in the brain and they are
all subject to random gene mutations, but why only mutations
in PSs channels, not in any other channels, are segregated with
early dementia? This is most likely because PSs channels are
more important to cognition than other channels. This may allow
a new look at the long-held notion that other, more abundant
Ca2+/cation channels such as NMDA, AMPA or rynodine recep-
tors play primary roles in cognition. So, PSs may be a more
relevant tool for studying cognition.
Have the Inhibitors of “β- or γ-Secretase”
Reduced Aβ?
Despite the unanswered questions in the “β- or γ-secretase” doc-
trine, a considerable number of studies have nonetheless followed
it and reported that their synthetic inhibitors have “successfully
reduced Aβ levels,” thus spurring many high-profile clinical tri-
als on the inhibitors. But such reports themselves have also left
disturbing questions.
For example, many studies have reported that inhibiting “β-
secretase”, alone, reduces Aβ (Evin et al., 2011). But a key implica-
tion of the studies has not been mentioned: “γ-secretase” would
not be important anymore, since it is not tackled yet the Aβ
level changed. On the other hand, however, many other studies
have also reported that inhibiting “γ-secretase,” alone, reduces
Aβ (Imbimbo and Giardina, 2011), thereby proving “β-secretase”
being unimportant by the same token.
Apparently, such mutually conflicting studies would defy each
another’s scientific values, especially since neither camp has dis-
cussed the implications of the other, an un-scientific manner.
More intriguingly, none of them has thought of the changes of
α-secretase, a vibrant and highly sensitive player that controls
the availability of full-length APPs in any cells that produce Aβ.
Can any drugs reduce cholesterol levels without affecting normal
degradation of lipids?
Moreover, the release of Aβ apparently involves two sequential
or simultaneous cleavages at its both ends, so how can a single
inhibitor reduce it? Further, if various proteases can be involved
in the release of heterogeneous Aβs, will inhibiting one of them
reduce the overall levels of the peptides significantly? What if
the compensatory effects of other proteases are also taken into
account?
Evidently, unless these questions are answered on the basis of
the established biological laws, it is perhaps premature to expect a
“miracle cure” by the inhibitors.
Why α-Secretase can be Identified
While the singular form for “β- or γ-secretase” is problematic, I
nevertheless think that it is correct for α-secretase for two reasons.
First, direct sequencing of the secreted APP by α-secretase from
a wide variety of cell types including insect and yeast has only
found its C-terminus ending near-uniformly at Aβ15/16 (Esch
et al., 1990; Anderson et al., 1991; Wang et al., 1991; Lowery
et al., 1991; Ramabhadran et al., 1993; Zhang et al., 1994), despite
other minor species being detected by highly sensitive methods.
Second, theoretically, the “double anchorage” of both APP and
α-secretase in the membrane, which explains the site-specific
APP α-cleavage, may not allow additional α-secretases there, a
redundant system.
Therefore, despite the proposed “two α-secretases,” constitu-
tional and stimulated (Lammich et al., 1999), it is my opinion
that there is only one α-secretase in APP processing, but exists
in two functional states: basal and stimulated in vitro, or efficient
and inefficient in vivo (Figure 2). Such experimental or age-related
changes perhaps also occur in other lifeline enzymes.
At the same time, the Ca2+-dependent nature of α-secretase, if
established, would preclude most other proteases in the repertoire
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as its reasonable candidates. I therefore believe that α-secretase
would be identified in the end.
What is Behind the Obsession for
“β-/γ-Secretases”?
Besides these scientific issues, I also noticed that there is a long-
existing and black-and-white question beyond scholarly debates.
This question should alert all of us.
Given the universal knowledge that boosting α-secretase
reduces Aβ, a rational and straightforward highway for
intervention and, particularly, that a full spectrum of effective
agents to do so have long been known (Chen, 1997; Mattson,
1997), why, then, is there such an obsession and fanatic commit-
ment to “inhibiting β- and γ-secretases,” a much more costly and
biologically twisting road even if possible, in the first place?
A shadowy motive may not be ruled out: only the latter road
brings more patents, sales and wealth, a “dark energy” that has
been driving AD research for too long and too passionately.
Making wealth aside, why knowingly skew research direction at
the expense of science and patients’ interests, even though it fits
NIA perception? A soul-searching by policymakers and some elite
researchers may be helpful.
For-profit studies have played important roles in medical his-
tory, especially in drug development stages. But a worrisome
reality in AD study is that they have played a heavy role in the
fact-finding stage, a subtle and curiosity-driven process that can
be unnoticeably tilted off course by non-science forces at the
key turning points (e.g., excessive aging or “bona fide disease”;
boosting brain health or “inhibiting toxins”). Meanwhile, such
forces may have also played a role in the making of the dogmatic
status of the unproven “Ca2+ overload” hypothesis (Khachaturian,
1994) (calcium channel blocker sales).
No wonder whymany commonsense issues can remain contro-
versial after 40 years (e.g., normal or “abnormal”; targeting aging
process or “cell-death”; Ca2+ deficiency or “excess” in aging) – in
the deepest roots, they may reflect, at least in part, the conflicts
between science and vested interests.
A Critical Decision for NIA
By recalling the process in which the field has shifted the study
focus from α-secretase to “β-/γ-secretases” over the years, I
noticed that the transition has happened perhaps in the following
footsteps.
(i) It has been established that α-secretase is sensitively regu-
lated bymany signal pathways (e.g., glutamatergic, choliner-
gic, ERK/MARK-, PKC-, energy related- and IP3-pathways,
among others). However, intervention design has stagnated,
because it is unpractical to target these many pathways at
once. At the same time, no common denominator for these
pathways has been validated and accepted.
(ii) This study impasse would allow the field to drift towards
metalloproteases – another dead end since unregulated pro-
teases, in the end, are unlikely to be re-activated by common
approaches for intervention. And if they are α-secretase,
then it may not explain why Aβ is protease-resistant (Chen
and Nguyen, 2014).
(iii) These gridlocks thus would set the stage for “β-/γ-
secretases” studies to boom. Under the powerful influences
of vested interests and NIA perceptions, such studies have
quickly overwhelmed the landscape and, meanwhile, inhib-
ited scholarly criticisms, the last line of defense for the
integrity of science.
Now, comparison of the three study directions suggests that
targeting α-secretase, a regulated enzyme, is the only rational
paradigm for intervention. However, a persistent obstacle here
is the lack of a common regulatory mechanism for the enzyme,
the bottleneck to the study progress. In this regard, I proposed
the concept of “Ca2+-dependent α-secretase” (Chen, 1997), or
“energy-Ca2+” as the common drug target, a proposal that is
supported by a solid and growing body of experimental evidence
and, especially, it has an unusual explanatory power for the sAD
features (Chen and Nguyen, 2014).
However, metalloproteases and “β-/γ-secretases” have also
been widely said to be “regulated” because they, too, are respon-
sive to the signal pathways (Imbimbo and Giardina, 2011; Lich-
tenthaler, 2012). Since Ca2+ is perhaps the only true signal
transduction-controlled protease regulator known today, I think
that metalloproteases and other proteases are not regulated, but
affected, by the activated signal pathways, whichwill trigger a wide
variety of metabolic and structural changes in the cell. Although
“regulate” and “affect” are difficult to be distinguished in vitro, it
must be kept in mind that they differ by specificity, exclusivity,
sensitivity, reversibility, profoundness and, particularly, feasibility
for intervention.
Nevertheless, the strongest anddirect blockage for the proposed
“Ca2+-dependent α-secretase” is the current “Ca2+ overload”
dogma, since the former concept points to a Ca2+ signal defi-
ciency in the aging brain, whereas the latter implicates “excessive”
signals there – two opposing and uncompromising intervention
approaches on a central drug target.
It is thus clear that this dogma is at the epicenter of the grid-
locks. By overlooking the energy-dependent and dynamic wave
natures of Ca2+ and by overly relying on its static changes in the
cell-death stage, this dogma lacks scientific rigor and panoramic
vision on the aging-to-sAD progression, yet being inappropriately
promoted by an NIA policymaker (Chen et al., 2011b). It thus has
authoritatively obstructed the understanding of the central role of
age-related Ca2+ early and normal changes in Aβ overproduction
(and also in tangle formation and cognitive decline; see below).
So, NIA faces hard options today: to revisit the dogma, or to let
the gridlocks to stay. This is a difficult but lifeline decision that
NIA and the field must make.
APP Mutations Disturb α-Processing, not
β-/γ-Processing
There are other interesting science issues to discuss. One of them
is: how do pathogenic APP mutations cause Aβ increase in early
onset familial AD (EOAD)?Thesemutations involve three groups:
Swedish, London, and Dutch, which are long believed “to render
β- or γ-processing more efficient” (except for Dutch mutations;
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FIGURE 4 | A proposed model for how APP mutations disturb
α-processing. No doubt, Dutch mutations can directly do so. London
mutations may also change the conformation of APP and disturb its binding to
α-secretase in a crowed membrane environment, thus reducing α-processing.
Swedish mutations, though at outside of the membrane, are embedded in the
glycocalyx layers at the immediate cell surface where the movement of this
section of APP relative to α-secretase is hindered, thus allowing the mutations
to affect α-processing. The Swedish mutations may also be made closer to
α-secretase by APP self-folding. A protective “Finnish” mutation is also
depicted.
Bagyinszky et al., 2014). But, this model is questionable now
because of the multiplicity of “β-/γ-secretases” and the rarity of
the mutations that make enzymatic reactions more efficient (see
above).
Upon a closer look at the issues, I now think it more likely that
these mutations increase Aβ by decreasing α-processing. For one
thing, this can explain the sources of the additional full-length
APPs. But is it reasonable?
No doubt, the model can directly explain the roles of the Dutch
mutations, which change the conformation of APP at a very close
vicinity to the α-cleaving site, thereby robustly disrupting the
interaction of APP with α-secretase (Figure 4). But, are other
mutations too far to do so?
It must be noted that the relative movements of APP and
α-secretase are constrained in the membrane. Such a crowed
microenvironment means that the conformational changes of
APP caused by London mutations may also perturb the bind-
ing of APP to α-secretase, thus reducing the α-cleavage. But
due to their farther distances to the α-site, London mutations
would be expected to have less potent effects than Dutch muta-
tions. Indeed, Dutch mutations cause dramatic Aβ deposits on
the blood vessels, leading to hemorrhage and early death of
the carriers (Levy et al., 1990; Hendriks et al., 1992), condi-
tions that are much severer than those caused by London muta-
tions.
Swedish mutations, on the other hand, are located at outside
of the cell, but may not move freely either, because the imme-
diate surface of the cell is embedded in the glycocalyx layers
(glycoproteins and polysaccharides). This may allow the confor-
mational changes brought by Swedish mutations in this section of
APP to also interfere with α-cleavage (Figure 4).
By contrast, if β- and γ-secretases are really “rate-limiting” in
Aβ genesis and their cleavages are really made “more efficient”
by the mutations, then Dutch mutations, due to their farther
distances to either the β- or γ-cleaving site than London and
Swedish mutations, would be expected to be the least potent in
overproducing Aβ – contrary to the observations.
Also interesting is that a protective mutation has recently
been found within the Swedish area (“Finnish mutation” A673T;
Jonsson et al., 2012) (Figure 4). I think that it may represent
a rare “gain-of-function” mutation that somehow enhances the
interaction of α-secretase and APP thus decreasing Aβ.
Why are Tau Fragments Much Longer
than Aβ?
The mechanism of origins of neurofibrillary tangles is unknown
today, despite intensive studies. While most current studies
assume an “overactivation” of protein kinases as the initial cause
(Cruz andTsai, 2004;Medina et al., 2011), we have proposed a new
model from a perspective of “inefficient calpain and calcineurin”
(the reasons for why not kinases nor other proteases and phos-
phatases involved were discussed elsewhere; Chen and Nguyen,
2014).
Now, I also modified this model slightly to further explain why
the deposited tau (PHF tau) is much longer than Aβ (Figure 5).
PHF tau is known to be truncated at both ends and the resulting
fragments start from around residue 230 to 391 (deduced from
the antibody-recognizing epitopes in the longest tau isoform 441;
Guillozet-Bongaarts et al., 2005; Iqbal et al., 2010). This region
harbors four microtubule-binding repeats (from residues 256 to
368). But why is PHF tau so much longer (about 160 amino acids)
than Aβ?
This may be because that tau, a calpain substrate, contains
several calpain-cleaving sites. Indeed, it has been suggested that
PHF tau contains as many as nine predicted calpain-cleaving
sites (Yang and Ksiezak-Reding, 1995). Since PHF tau is phos-
phorylated, at least one calcineurin-acting site should reside in
this region and the site should also be exclusively accessible by
calcineurin (Figure 5A). So, after both calcineurin and calpain
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FIGURE 5 | A new model for how PHF tau is formed, why it is much
longer than Aβ and is also phosphorylated. (A) Tau contains multiple
calpain (Calpn)-acting sites and at least one calcineurin (CaN)-acting site
within its four-repeat regions (from residue 256 to 368). Ca2+-dependent
calpain and calicineurin recognize tau in a specific and exclusive manner
and completely proteolyze and dephosphorylate tau in the young.
(B) During aging, however, the two enzymes are inefficient so tau will
accumulate and will not be attacked by any other proteases and
phosphatases at the same sites but will be truncated alternatively by
many non-specific proteases at other sites. Thus, their core fragments
containing the calpain- and calcineurin-acting sites will be spared and
deposited with varying lengths that are much longer than Aβ, and also
stay un-dephosphorylated, or seemingly “hyperphosphorylated”, in the
aging brain.
become inefficient during aging, tau will not be attacked by
any other phosphatases or proteases at the two enzymes’ native
acting sites, but are truncated into fragments that encompass
those sites. Thus, these fragments would stay un-dephosphorylated
(Figure 5B). Indeed, the term “un-dephosphorylated” is more
accurate than “hyperphosphorylated,” which proactively implies
an “overactivated” process. In addition, the model also predicts
that the PHF tau fragments will have varying lengths at their both
ends, similar to Aβs.
Of particular interest is thatmany pathogenic genemutations in
tau have been found to cause severer and earlier tangle formation
in frontotemporal dementias (FTDs), but themechanism involved
is unknown. Now, I notice that a vast majority of these muta-
tions are located within or near the predicted calpain/calcineurin-
acting region (Wolfe, 2009). Thus, it is reasonable to believe that
the mutations cause tangle formation mainly by changing the
conformation of tau, thereby reducing its sensitivity to calpain and
calcineurin. This reinforces the central roles of Ca2+ signaling and
two Ca2+-dependent enzymes in the tangle formation.
Alternative to this model, other proteases (e.g., caspases and
proteasomes) and phosphatases (e.g., PP2A, PP1A, PP1B and
tyrosine phosphatase) have also been suggested to be respon-
sible for PHF tau formation. These models need to explain:
(a) how PHF tau, if produced by them, can stay and be
protease-/phosphatase-double resistant; and (b) why it is selec-
tively deposited amongmany other proteins (protein “misfolding”
or aggregation may not explain it; see above).
sAD vs. EOAD: Two Different Diseases or
“the Same Disease”?
The mutation-initiated mechanisms for plaques and tangles in
EOAD/FTDs (by changed APP and tau conformations, the acci-
dental events) contrast sharply with the aging-initiated mecha-
nisms for the “same” plaques and tangles in sAD (by changed
protease activity, a natural event as age advances).
This clearly indicates that sAD differs fundamentally from
EOAD by origin, and indeed, they can be clinically distinguished
by age 60 and eventual prevalence (< or > 50%), two defining
criteria that separate senile disorders and discrete diseases (Chen
et al., 2011a). This assertion thus challenges the NIA perception
that EOAD and sAD are “the same disease,” the centerpiece in the
“discrete disease” definition for sAD (Khachaturian, 2008).
Notably, this NIA perception is responsible for the conundrum
of APP processing today. It should be pointed out that the “two
competing pathways” model (Figure 1), if used only for EOAD,
is correct in essence, since APP/PS mutations do change the
balance of the two pathways at the same time (in the youngmutant
hosts) and they are indeed independent of each other (normal
vs. mutation). So, the only problem is that a correct model in
one disease has been incorrectly used in another disease (Selkoe,
2005) – a serious consequence of “the same disease” perception.
Another one of themany far-reaching consequences of the NIA
perception is that it promotes the wide-spread use of the mutant-
based animal models today for screening and testing drugs that
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aremostly intended for sAD intervention. But suchmodels mimic
the conditions of EOAD, not sAD. To this end, I proposed that the
best animal model that mimics the sAD conditions should be the
oldest wild-type animals tested in comparison with young animals
(Chen, 1998b).
Myunderlying reason for this proposal is that sAD study should
be essentially the aging study (i.e., comparing old with young),
thereby revealing age-related normal defects for intervention, a
commonsense in the studies of senile osteoporosis and atheroscle-
rosis (targeting bone loss and slowed-digestion of cholesterol at
their early phases). Unfortunately, most studies on sAD today
are instead the “disease study” (comparing patients with healthy),
thus uncovering numerous “aberrant pathways” in the later or
cell-death stages, but too late to have any preventive values (Chen
et al., 2011b).
Conclusion
Plaques and tangles are the products of aging, similar to
cholesterol or mineral deposits, at least at their initial phases. Had
this commonsense been kept in mind, sAD would not have been
such a super-complex disease today.
But, sAD study has not been guided by commonsense con-
ceptions. Its “curable disease” definition – a tempting optimism
but beyond what science can prove or deliver – preconditions
us to view plaques or tangles as its “culprits,” or products of
“overactivated” proteases and kinases. So their inhibitors must
cure the disease – a point of no return with repetitive trial failures
but determinedly ongoing – an unfalsifiable faith that will not fade
anytime soon (Selkoe, 2011; De Strooper, 2014).
At the same time, the “Ca2+ overload” dogma blocked the
understanding of the role of Ca2+ in the formation of plaques
and tangles. This, in turn, has forced the field to turn to myriad
other factors: β- and γ-secretases, nicastrin, Pen2, Aph-1, met-
alloproteases, cholesterol, CDK, GSK, p35, p25, and the list still
expanding.
Such scattering studies would render the origin of plaques and
tangles a super-complex and ever diverging – thus hopeless –
maze, since a healthy research trend must be converging over
time (narrowing down the suspects). This may be why there has
been a deepening dissociation between paper publication and
understanding of sAD. As a matter of fact, Ca2+ is a single central
regulator in cognition – or “Achilles’ heel” of sAD – so studying
any other factors may only address secondary or non-central
issues in the disease (akin to study diabetes but not focusing on
insulin-centered pathways, or study atherosclerosis not focusing
on lipid metabolisms).
I, therefore, call for a game change in sAD study, particularly
in the areas that are contaminated by vested interests. This issue
awaits the decision of NIA and all researchers. Ignoring or delay-
ing this long overdue decision will further hamper the rational
intervention in sAD, a mission that has been delayed for 40 years.
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